BioMarin Pharmaceutical Inc.

Form 483 issued April 2, 2021 · Novato, California

Inspection
Apr 2, 2021
Observations
2
Pages
2
FEI number
3004079983

In short: On April 2, 2021, FDA issued a Form 483 with 2 observations to BioMarin Pharmaceutical Inc. in Novato, California (FEI 3004079983) after an inspection that ran Apr 2, 2021. The investigator was Uttaniti Limchumroon. Most observations concern laboratory controls; the most-cited regulation is 21 CFR 211.160 (general requirements).

At a glance

2 of 2 observations on this 483 concern laboratory controls.

Laboratory controls2

Most cited: 21 CFR 211.160 (2×)

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    Your firm does not have a written established procedure for requesting and shipping samples to the…

  2. 02

    Your firm does not have a written procedure governing the process of receiving, reviewing, and filing…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at BioMarin Pharmaceutical Inc.?

FDA listed 2 observations on this Form 483, mostly about laboratory controls. The most-cited regulation is 21 CFR 211.160 (general requirements). The opening words of each observation are shown on this page.

Who inspected BioMarin Pharmaceutical Inc.?

Uttaniti Limchumroon is named on this Form 483, for the inspection of Apr 2, 2021. Each investigator has a profile showing what they cite most.

When was BioMarin Pharmaceutical Inc. inspected by FDA?

The inspection ran Apr 2, 2021, and the Form 483 is dated April 2, 2021.

How do I get the full Form 483 for BioMarin Pharmaceutical Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free